# Concordance between a novel RT-PCR assay and FISH for the detection of EML4-ALK fusion genes in FFPE specimens

Eirini Papadopoulou, Samuel Murray, George Nasioulas

GeneKOR S.A., 52 Spaton Ave., 15344 Gerakas, Athens, Greece

### Background

Echinoderm microtubule-associated protein-like 4anaplastic lymphoma kinase (EML4-ALK) is a fusiontype protein tyrosine kinase identified recently in a subset of human lung carcinomas. The recent licensing approval of Crizotinib (PF0234-1066, Pfizer) in NSCLC patients harboring the EML4-ALK fusion will intensify screening efforts. Due to unknown differences in treatment outcomes between the fusion variants, methods other than FISH will be required.

The scope of the study was to design a robust RT-PCR assay that permits sensitive detection of all published EML4-ALK variants.

## Methods

The study included FFPE specimens from NSCLC patients without EGFR or K-RAS mutations. Detection of all EML4-ALK fusions was achieved using a reverse transcription-PCR (RT-PCR). For this reason specific primers that selectively enhanced EML4-ALK transcripts 1, 2, 3a, 3b, 4, 5a, 5b, 6, 7, "4" and "5" were designed (figure 1). Synthetic DNA fragments for each variant were cloned using the pCR2.1 cloning vector and used as positive controls (figure 2). DNA sequencing analysis was performed to confirm the specificity of the obtained PCR products (figure 3).

FISH analysis was performed using the FDA approved kit «Vysis ALK Break Apart FISH Probe Kit» (Abbot)







#### Additional variants reported and identified by our assay 3c, d, e, f, g, h, 6b, 8a, b

### Results

• Sensitivity of the test: 22 copies of the translocation could be detected per µg of RNA.

• All EML4-ALK FISH positive samples (n=7) were positively subtyped using RT-PCR and sequencing.

• None of the 123 FFPE specimens, obtained from Greek NSCLC patients, were positive for the EML4-ALK fusion.

#### Discussion

• For the detection of EML4-ALK transcripts a variety of methods have been used, including immunohistochemistry, fluorescent in situ hybridization, and reverse transcriptase polymerase chain reaction (RT-PCR).

 Pathological review was obtained for all samples and macro-dissection was used to ensure a tumor cell content (%TCC) of >75% in all possible cases (figure 4). A high concordance rate was observed in our series (figure 5) between FISH and RT-PCR.

Limited data exists regarding the incidence and spectrum of EML4-ALK variants, RT-PCR will be required for such classification. Here we demonstrate that RT-PCR is a method of high sensitivity and specificity for the detection of EML4-ALK variants and their classification. Once standardized this may offer an alternative analytical technique to FISH, in the diagnostic setting.



Figure 4. Use of macrodissection for the selection of cancer tissue.



Figure 5: Sequencing analysis for the V3 EML4-ALK variant and corresponding FISH.

### Conclusions

• We have designed a robust RT-PCR assay that permits the sensitive detection of all published EML4-MLK variants and it is feasible for commonly available materials such as FFPE specimens, cytological specimens and other aspirates.

• Concordance between the results obtained by RT-PCR and FISH analysis is warranted in a larger series.

#### References

1. Soda M. et al. Identification 2007 Aug 2;448(7153):561-6. ication of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature

2. Takahashi T. et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann

Jakanashi 1: et al. Clinicopathologic features of non-small-cent lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010 Mar;17(3):889-97.
Shaw AT. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10;27(26):4247-53.
Horn L. Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol. 2009 Sep 10;27(26):4232-5. Epub 2009 Aug 10